Daily Brief Health Care: 3SBio Inc, UltraGreen.ai, Apellis Pharmaceuticals, Bristol Myers Squibb Co, Chordia Therapeutics, Cooper Cos, Genmab A/S, Halozyme Therapeutics, Jazz Pharmaceuticals and more

• Pharma-Play 3SBio Inc (1530 HK) has announced the spin-off and listing of 87.16%-held Mandi (MANDI HK)  on the HKEx. 
• 3SBio will distribute its stake in-specie. There will be a concurrent global offering, the details of which are still to be fleshed out. 
• Mandi (MANDI HK), a ” hair loss and weight management treatments” solutions provider, accounted for 17% of 3SBio’s revs in the 1H25, and 12.5% of profit.

• UltraGreen.AI (2594794D SP) is looking to raise US$400m in its upcoming Singapore IPO.
• Ultragreen is a global leader in Fluorescence Guided Surgery (FGS), a surgical approach that helps doctors see things inside the body that are normally invisible under regular white light.
• In this note, we look at the company’s past performance.

• Apellis is a commercial-stage biopharmaceutical company with a first-in-class C3 inhibitor platform, having successfully launched two products: SYFOVRE for Geographic Atrophy (GA) and EMPAVELI for Paroxysmal Nocturnal Hemoglobinuria (PNH).
• The company is experiencing a significant revenue ramp, driven by the strong uptake of SYFOVRE, the first-ever approved treatment for GA, addressing a large and underserved market. This has shifted the company’s financial profile towards profitability.
• Key risks center on the commercial execution and long-term safety profile of SYFOVRE, particularly concerning rare instances of retinal vasculitis, and intense competition in both the GA and PNH markets from established and emerging players.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Bristol Myers Squibb has once again found itself in the spotlight for all the wrong reasons, with the company announcing that it has halted a Phase 3 trial of its experimental blood thinner, milvexian.
• The trial, which targeted patients recovering from acute coronary syndrome, was deemed unlikely to meet its primary endpoint by an independent data monitoring committee.
• The news, which broke on November 14, 2025, led to a 3.1% drop in BMY shares, contributing to a year-to-date decline of 17%.

Key points (machine generated)

• Chordia Therapeutics, a biotech firm from Takeda, is developing the CLK inhibitor rogocekib (CTX-712) for blood cancer treatment.
• The company aims to apply for regulatory approval for rogocekib by late 2028, following promising Phase 1 trial results in Japan.
• Chordia went public in June 2024 and plans to handle manufacturing and sales in Japan while exploring international licensing opportunities.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Key points (machine generated)

• Chordia Therapeutics, a biotech company from Takeda, is developing anticancer drugs, focusing on rogocekib, a CLK inhibitor.
• The company plans to apply for approval of rogocekib in the second half of 2028 after successful Phase 1 trials in Japan.
• Chordia went public in June 2024 and manages operations from research to clinical studies, with plans for in-house manufacturing and international licensing.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• Cooper Companies surged over 6.5% in premarket trading following a bombshell report that activist investor Jana Partners has taken a stake in the company and is pushing for sweeping strategic changes, including a high-profile merger of its contact lens unit with rival Bausch + Lomb.
• The news, first reported by the Wall Street Journal, has sent shockwaves through the vision care industry.
• Jana, known for catalyzing structural change across multiple sectors, is also urging Cooper to improve its capital allocation and returns, hinting at broader dissatisfaction with management’s operational strategy.

• Genmab A/S is making headlines again, this time by sealing the U.S. leveraged finance market’s biggest M&A funding since April with a $4.5 billion raise through junk bonds and a leveraged loan.
• The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29, 2025.
• This bold move comes amid Genmab’s rapidly scaling commercial operations and late-stage pipeline expansion, headlined by drugs like EPKINLY and Rina-S.

• Halozyme Therapeutics’ third quarter 2025 results show a strong financial performance driven by its ENHANZE drug delivery technology and significant growth in royalty revenue.
• The company reported an impressive 52% increase year-over-year in royalty revenue, reaching $236 million.
• This growth, along with total revenue of $354 million, reflects a 22% increase year-over-year.

• In a week dominated by biotech headlines, few announcements carried more weight than the positive Phase 3 data for Ziihera, the HER2-targeted bispecific antibody developed by Jazz Pharmaceuticals and Zymeworks.
• On November 18, 2025, Jazz Pharmaceuticals reported that the HERIZON-GEA-01 trial of Ziihera (zanidatamab) in first-line treatment of HER2-positive gastroesophageal adenocarcinoma (GEA) had met its endpoints, driving strong progression-free survival and overall survival results.
• This milestone marks a significant leap in treatment options for one of the world’s most aggressive and deadly cancers.